Insight

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma

my.clevelandclinic.org

Dec 20, 2024, 10:22

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma

Jame Abraham,Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on X:

“Bispecific Antibody Glotiftamab Combination with Chemoimmunotherapy Safe and Effective for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy.”

More posts featuring Jame Abraham.

Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.

Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).

bispecific antibody Cancer research cancer treatment chemoimmunotherapy Cleveland Clinic Diffuse Large B-Cell Lymphoma Glotiftamab Jame Abraham Oncology relapsed cancer

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial